GVR Report cover Cellular Health Screening Market Size, Share & Trends Report

Cellular Health Screening Market Size, Share & Trends Analysis Report By Test Type (Single Test Panels, Multi-test Panels), By Sample Type (Blood, Serum Urine, Saliva), By Collection Site, By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-3-68038-972-2
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Market Size & Trends

The global cellular health screening market size was valued at USD 2.78 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2023 to 2030. Over the projected period, the importance of precision medicine is expected to increase along with the requirement to analyze biomarkers for aging and cellular health in general. In addition, cellular health screening plays a crucial role in monitoring the body’s reaction to treatment regimens, which is anticipated to contribute to the growth of the market. Companies involved in delivering cellular health screening goods and services noticed a reduction in their sales and base testing volume as a result of the COVID-19 pandemic.

Canada Health Screening market size and growth rate, 2023 - 2030

In addition to the pandemic-related mandates by the government, the transportation restrictions and limitations on the import and export of raw materials and goods disrupted the supply chain. Owing to the decrease in demand as a result of supply chain disruption, many businesses have broadened their product lines to include COVID-19 molecular and antibody testing, which can equally counterbalance the decline in base testing volume.

The use of home diagnostic tests is significantly rising globally. The growing number of campaigns to educate the public about the signs of chronic diseases and how to prevent them in order to contain disease epidemics are expected to fuel growth. As a result, there is a significant demand for cellular health screening kits and services due to greater patient awareness. Additionally, the use of these devices helps to optimize prompt treatment decisions, increases the effectiveness of care given, and dramatically lowers diagnosis costs, especially in resource-constrained countries with inadequate laboratory facilities.

Numerous studies have shown a connection between malignancies and telomere length. Telomere shortening as a tumor suppressor turns out to be a significant factor in cancer that has progressed more severely. Although it has been demonstrated that a range of variables, including infections, inflammation, and stress, affect the length of telomeres and inflammation, in particular, causes oxidative stress, which, in turn, causes telomere erosion. According to research, telomere maintenance plays a significant role in how aging and related disorders are affected by environmental, lifestyle, and genetic factors. As a result, it is crucial to know how quickly telomeres change in order to understand biological aging and hereditary illnesses. Furthermore, telomere length loss has been linked to pathologies associated with aging, including cancer, cardiovascular illnesses, and weakened immune systems. The need for cellular health screening is projected to grow over the years with the rising incidence of chronic diseases, which further drives the market.

Growing awareness campaigns by numerous organizations throughout the world have played a significant role in increasing the demand for testing-based preventive healthcare products and services. One of the key factors anticipated to drive the market during the forecast period is collaborative efforts by organizations such as the CDC, the U.S. Preventive Services Task Force (USPSTF), the National Cervical Cancer Coalition, and the WHO.

In addition, major industry companies are launching campaigns to raise awareness about cervical and vaginal cancer screening to prevent mortality. For instance, as per the article published by theguardian.com, in February 2022, an awareness campaign has been launched in England to increase life-saving screening. This campaign was launched by the Department of Health and Social Care.

Test Type Insights

The single test panels segment held the largest share of 79.08% in 2022. Among the cellular health screening tests for telomere, inflammation, oxidative stress, and heavy metals, the telomere single test panel is expected to grow at the fastest rate over the forecast period. This can be attributed to various research studies showing the correlation of telomere length on multiple molecular and cellular functions. Moreover, the launch of new testing devices for the detection of telomere length further contributes to the growth. For instance, in September 2021, Genomic Vision launched TeloSizer to boost the use of telomere for biomarker discovery via its precise and quantitative detection.

The multi-test panels segment is estimated to witness the fastest growth during the forecast period. The utilization of these panels for screening multiple biomarkers during a single run has resulted in many advantages such as diagnostic competence, precision, and reduced costs in health care settings. These reasons are anticipated to increase the inclination toward multi-test panels rather than single-use panels in the future.

Sample Type Insights

Blood sample dominated the market with a share of 47.41% in 2022. The frequent use of blood samples by clinicians and the application of diagnostic kits for evaluating various disease conditions, organ functioning, and risk factor analysis are the factors supporting the growth of the segment. Additionally, the launch of new diagnostic devices that use blood for detection and screening is boosting market growth. For instance, a blood-testing startup, Osler is tapping investors for funds before the big launch of its diagnostic device. The new technology will deliver results in 10 minutes and it aims at providing cheap blood tests.

Urine sample held the second largest market share and is expected to grow at a lucrative rate in the forecast period. Urine collection is patient-friendly as it is non-invasive and much quicker because it doesn’t require technical personnel. Research has also demonstrated that oxidative stress can be successfully evaluated from urine screening. For instance, in a research article published in July 2020, researchers from Japan proved that the presence of pteridine derivatives in urine is associated with oxidative stress and smoking. Thus, the increased testing of oxidative stress in the human body is also expected to fuel the growth of urine sample type screening in the market.

Collection Site Insights

In 2022, the hospital segment accounted for the largest revenue share of 39.30%. For the majority of the population, hospitals are the center for primary diagnosis and treatment. The use of diagnostic kits for both in-patients and out-bound patients for health screening is one of the major factors contributing to the growth. Moreover, the presence of medical professionals and the recommendation of diagnostic tests for disease identification are fueling the growth of the market. The presence of sample collection sites, skilled professionals, and advanced diagnostic techniques in one place is anticipated to further contribute to the growth.

Global Cellular Health Screening Market share and size, 2022

The home segment is estimated to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing awareness regarding health and self-sampling adoption in major markets. The adoption of self-sampling is because it is user-friendly and doesn’t require specific infrastructure or trained professionals. Moreover, the COVID-19 pandemic led to the mass preference for home collections due to limited movements and this preference will continue even in the years to come. For example, Lab Corp announced in April 2022 that it has launched a home collection service for various diagnostic and screening test offerings of the company.

Regional Insights

North America accounted for the largest share of 49.61% of the cellular health screening market in 2022. The rising awareness regarding health among individuals driving the Healthy Life Expectancy (HALE), growing healthcare expenditure, and government funding for preventative healthcare are some of the key contributing factors in this region. Furthermore, the presence of major key players, easy adoption of new technologies, and the burden of infectious and chronic diseases in the population are contributing to regional growth.

Cellular Health Screening Market Trends, by Region, 2023 - 2030

Asia Pacific is expected to emerge as the fastest-growing regional market over the forecast period. This is owing to the presence of a growing population that contributes to a larger patient pool and the developing healthcare infrastructure due to increasing economies. The improved adoption of tests and health consciousness among adult individuals are the key driving factors in the Asia Pacific. Moreover, the increased research on telomere for senescence and government initiatives for the prevention of diseases is supporting regional growth.

Key Companies & Market Share Insights

The presence of both well-established along with emerging players is likely to create a competitive scenario in the market. The launch of new technologies and products and collaborations and partnerships for geographical expansions further strengthen the market hold of the players. For instance, in April 2023, Virtua Health launched a mobile health & cancer screening unit with the aim of expanding access to critical cancer diagnostics. Also, in January 2023, Atomo Diagnostics, an Australian diagnostic company, entered into a long-term agreement with NG Biotech SAS to manufacture and distribute rapid blood-based pregnancy tests for both home and professional use in prominent markets. Some prominent players in the global cellular health screening market include:

  • Life Length

  • SpectraCell Laboratories, Inc.

  • RepeatDx

  • Cell Science Systems

  • Quest Diagnostics Incorporated

  • Laboratory Corporation of America Holdings

  • OPKO Health, Inc.

  • Genova Diagnostics (GDX)

  • Immundiagnostik AG

  • DNA Labs India

Cellular Health Screening Market Report Scope

Report Attribute


Market size value in 2023

USD 3.03 billion

Revenue forecast in 2030

USD 5.62 billion

Growth rate

CAGR of 9.2% from 2023 to 2030

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2030

Report updated

May 2023

Quantitative units

Revenue in USD million/billion and CAGR from 2023 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Test type, sample type, collection site, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; South Korea; Australia; Thailand; Brazil; Mexico; Argentina; South Africa; UAE; Saudi Arabia; Kuwait

Key companies profiled

Life Length, SpectraCell Laboratories, Inc., RepeatDx, Cell Science Systems, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, OPKO Health, Inc., Genova Diagnostics (GDX), Immundiagnostik AG, DNA Labs India

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Cellular Health Screening Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global cellular health screening market on the basis of test type, sample type, collection site, and region:

Global Cellular Health Screening Market Report Segmentation

  • Test Type Outlook (Revenue, USD Million, 2018 - 2030)

    • Single Test Panels

      • Telomere Tests

      • Oxidative Stress Tests

      • Inflammation Tests

      • Heavy Metals Tests

    • Multi-test Panels

  • Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

    • Blood

    • Saliva

    • Serum

    • Urine

  • Collection Site Outlook (Revenue, USD Million, 2018 - 2030)

    • Home

    • Office

    • Hospital

    • Diagnostic Labs

  • Regional Outlook (Revenue, USD Million; 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Thailand

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • UAE

      • Saudi Arabia

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.